The Lancet: November 22, 2012

David Cunningham from the Royal Marsden Hospital in London assesses the potential of regorafenib in the treatment of colorectal cancer and gastrointestinal stromal tumours.Continue this conversation on social!Follow us today at...https://twitter.com/thelancethttps://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttps://linkedIn.com/company/the-lancethttps://youtube.com/thelancettv